Weekly Research Analysts’ Ratings Updates for Edwards Lifesciences (EW)

Several brokerages have updated their recommendations and price targets on shares of Edwards Lifesciences (NYSE: EW) in the last few weeks:

• 4/29/2024 – Edwards Lifesciences was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 4/26/2024 – Edwards Lifesciences had its price target raised by analysts at Wells Fargo & Company from $94.00 to $99.00. They now have an “overweight” rating on the stock.
• 4/26/2024 – Edwards Lifesciences had its price target raised by analysts at Piper Sandler from $85.00 to $88.00. They now have a “neutral” rating on the stock.
• 4/26/2024 – Edwards Lifesciences had its price target lowered by analysts at Evercore ISI from $92.00 to $89.00. They now have an “in-line” rating on the stock.
• 4/26/2024 – Edwards Lifesciences had its price target raised by analysts at Stifel Nicolaus from $83.00 to $85.00. They now have a “hold” rating on the stock.
• 4/15/2024 – Edwards Lifesciences had its price target raised by analysts at Royal Bank of Canada from $95.00 to $101.00. They now have an “outperform” rating on the stock.
• 4/11/2024 – Edwards Lifesciences had its price target raised by analysts at Mizuho from $95.00 to $105.00. They now have a “buy” rating on the stock.
• 4/4/2024 – Edwards Lifesciences had its price target raised by analysts at Evercore ISI from $86.00 to $92.00. They now have an “in-line” rating on the stock.
• 4/3/2024 – Edwards Lifesciences had its price target raised by analysts at Citigroup Inc. from $90.00 to $98.00. They now have a “neutral” rating on the stock.
• 3/26/2024 – Edwards Lifesciences was upgraded by analysts at OTR Global from a “mixed” rating to a “positive” rating.
• 3/21/2024 – Edwards Lifesciences had its price target raised by analysts at Morgan Stanley from $95.00 to $103.00. They now have an “overweight” rating on the stock.
• 3/20/2024 – Edwards Lifesciences was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 3/18/2024 – Edwards Lifesciences had its price target raised by analysts at Oppenheimer Holdings Inc. from $93.00 to $100.00. They now have an “outperform” rating on the stock.
• 3/12/2024 – Edwards Lifesciences was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 3/7/2024 – Edwards Lifesciences was upgraded by analysts at Bank of America Co. from a “neutral” rating to a “buy” rating.

Edwards Lifesciences Price Performance

Shares of EW stock traded down $1.28 during trading hours on Tuesday, hitting $84.67. The company’s stock had a trading volume of 2,881,572 shares, compared to its average volume of 3,828,306. The business has a fifty day moving average of $90.27 and a 200-day moving average of $79.06. The stock has a market cap of $50.97 billion, a price-to-earnings ratio of 36.50, a P/E/G ratio of 4.28 and a beta of 1.05. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. The business had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Heisz Leslie Stone sold 7,056 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $86.45, for a total transaction of $609,991.20. Following the sale, the director now owns 26,980 shares in the company, valued at $2,332,421. The disclosure for this sale can be found here. Insiders sold a total of 194,004 shares of company stock valued at $17,166,254 in the last ninety days. Corporate insiders own 1.27% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds have recently made changes to their positions in EW. Norges Bank acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $648,540,000. Brown Advisory Inc. boosted its stake in Edwards Lifesciences by 20.1% during the 4th quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock worth $1,386,333,000 after acquiring an additional 3,048,274 shares during the last quarter. CIBC Private Wealth Group LLC boosted its stake in Edwards Lifesciences by 197.0% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,446,758 shares of the medical research company’s stock worth $262,815,000 after acquiring an additional 2,286,119 shares during the last quarter. AustralianSuper Pty Ltd bought a new position in Edwards Lifesciences during the 4th quarter worth approximately $168,519,000. Finally, Bank of New York Mellon Corp raised its holdings in Edwards Lifesciences by 9.5% during the 1st quarter. Bank of New York Mellon Corp now owns 18,973,304 shares of the medical research company’s stock worth $1,813,089,000 after buying an additional 1,644,869 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.